Aura Biosciences Files 8-K

Ticker: AURA · Form: 8-K · Filed: 2024-10-17T00:00:00.000Z

Sentiment: neutral

Topics: sec-filing, 8-k, regulatory

TL;DR

Aura Biosciences filed a routine 8-K, no major news yet.

AI Summary

Aura Biosciences, Inc. filed an 8-K on October 17, 2024, reporting on other events and financial statements. The filing does not contain specific details about new material events, significant financial figures, or material agreements within the provided text.

Why It Matters

This filing indicates Aura Biosciences is providing updates to the SEC, which could include routine disclosures or information relevant to investors monitoring the company's regulatory compliance.

Risk Assessment

Risk Level: low — The provided text is a standard 8-K filing notification without specific material events, making the immediate risk assessment low.

Key Players & Entities

FAQ

What specific items are being reported in this 8-K filing?

The filing indicates it covers 'Regulation FD Disclosure', 'Other Events', and 'Financial Statements and Exhibits'.

When was the earliest event reported in this filing?

The earliest event reported is dated October 17, 2024.

What is Aura Biosciences, Inc.'s principal executive office address?

The principal executive offices are located at 80 Guest Street, Boston, Massachusetts 02135.

What is the Commission File Number for Aura Biosciences, Inc.?

The Commission File Number is 001-40971.

What is the SIC code for Aura Biosciences, Inc.?

The Standard Industrial Classification (SIC) code is 2836, for BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).

Filing Stats: 1,152 words · 5 min read · ~4 pages · Grade level 14.4 · Accepted 2024-10-17 17:10:59

Key Financial Figures

Filing Documents

Forward Looking Statements

Forward Looking Statements Statements contained under this Item 8.01 regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements about the initiation, timing, progress, results and cost of the Company's research and development programs and the Company's current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and the Company's research and development programs; statements regarding the Company's expectations for an improved quality of life of patients after treatment with bel-sar and changes to the treatment paradigm for patients; statements regarding the Company's beliefs and expectations for the high unmet medical need for an effective local treatment in urologic oncology to preserve organ function; and the size and growth potential of the markets for the Company's product candidates and the Company's ability to serve those markets. Any forward-looking statements are neither promises nor guarantees, and investors should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including, without limitation, uncertainties inherent in clinical trials and in the availability and timing of data from ongoing clinical trials; the expected timing for submissions for regulatory approval or review by go

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release Dated October 17, 2024. 99.2 Virtual Urologic Oncology Investor Event Presentation of the Company. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aura Biosciences, Inc. Date: October 17, 2024 By: /s/ Elisabet de los Pinos Elisabet de los Pinos President and Chief Executive Officer

View on Read The Filing